This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Jane Larkindale
VP Clinical Science at PepGen Inc.


Jane Larkindale serves as the Vice President of Clinical Science at PepGen. Jane has dedicated the past 15 years of her career to accelerating therapy development for rare diseases, with a focus on neuromuscular diseases. Prior to PepGen, Jane was Executive Director at the Critical Path Institute where she conceived of and led the Rare Disease Cures Accelerator, Data and Analytics Platform, Duchenne Regulatory Science Consortium and multiple other disease specific consortia. Prior to the Critical Path Institute, Jane held the position of Vice President of Research Development at the Friedreich’s Ataxia Research Alliance and at the Muscular Dystrophy Association. Jane is a molecular biologist by training, having completed her D.Phil. (Ph.D.) in the Department of Plant Sciences at Oxford University, which she attended on a Rhodes Scholarship.

Agenda Sessions

  • Positive Results from a First-in-Human Study Support Continued Development of PGNEDO51 for the Treatment of Duchenne Muscular Dystrophy (DMD)